NATURE . COM {}

Matching Content Categories {📚}

• Education
• Health & Fitness
• Non-Profit & Charity

Content Management System {📝}

What CMS is nature.com built with?

Custom-built

No common CMS systems were detected on Nature.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of nature.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month


Based on our best estimate, this website will receive around 5,000,058 visitors per month in the current month.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Nature.com Make Money? {💸}

Display Ads {🎯}

Direct Advertisers (10)

Reseller Advertisers (38)

How Much Does Nature.com Make? {💰}

Display Ads {🎯}

$63,100 per month
Our calculations suggest that Nature.com earns between $42,042 and $115,617 monthly online from display advertisements.

Keywords {🔍}

dose, patients, cancer, study, pimasertib, voxtalisib, inhibitor, article, phase, combination, daily, day, nature, adverse, subjects, google, scholar, expansion, mek, advanced, solid, escalation, safety, tumour, response, pik, dosing, events, rpd, disease, cycle, cas, pikmtor, mtd, treatment, cohorts, tumours, efficacy, included, pathways, grade, mapk, tolerability, including, oral, patient, activity, melanoma, pathway, toxicity,

Topics {✒️}

nature portfolio privacy policy human services advertising nature 417 nature research fuding participating institutions research funding social media favourable therapeutic index undergoing active development reprints multi-targeted kinase inhibitors double-sided niche regulation therapeutic index her2-directed drug conjugate database lock date biomarker development open-label chronic low-grade symptoms drug-drug interactions consisting alpha-specific pi3k inhibitor revised recist guideline pi3k/mtor inhibitor gsk2126458 treatment-emergent adverse events pi3k/akt/mtor pathway pi3k/akt/mtor pathway previous anti-cancer therapy ras/raf/mek/erk reversible dual pan-class oral pan-pi3k inhibitor pharmacokinetic drug-drug interactions treatment-related adverse events pi3k/mtor signalling pathways phase ib dose-escalation mtorc1/mtorc2 pathway signalling 16 long-term tolerability limited anti-tumour activity pi3k/mtor pathway inhibition pi3k/mtor inhibitors pf-04691502 kras-mutant ovarian cancers pimasertib-resistant human lung tolerability data generated pi3k/mtor pathways simultaneously tumour-specific expansion cohorts pi3k/mtor inhibitor xl765 pi3k/mtor inhibitor voxtalisib permissions author correspondence

Questions {❓}

• Drugging the undruggable RAS: Mission possible?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:A phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K/MTOR inhibitor voxtalisib in patients with advanced solid tumours
         description:This phase Ib study evaluated the safety, maximum-tolerated dose (MTD), pharmacokinetics, pharmacodynamics, and preliminary efficacy of pimasertib (MSC1936369B), a MEK1/2 inhibitor, in combination with voxtalisib (SAR245409), a pan-PI3K and mTORC1/mTORC2 inhibitor, in patients with advanced solid tumours. This study included a dose escalation and expansion in patients with select tumour types and alterations in the MAPK or PI3K pathways. A 3 + 3 design was used to determine MTD. Patients were evaluated for adverse events and tumour response. 146 patients were treated, including 63 in dose escalation and 83 in expansion. The MTD was pimasertib 90 mg and voxtalisib 70 mg daily. Based on the safety profile, the recommended phase 2 dose (RP2D) was pimasertib 60 mg and voxtalisib 70 mg. The most frequent treatment-emergent adverse events (TEAEs) were diarrhoea (75%), fatigue (57%), and nausea (50%). Responses included a complete response in one patient (1%), partial response in five (5%), and stable disease in 51 (46%). At the RP2D, 74 patients required dose interruption (73%), 20 required dose reduction (20%), and 26 discontinued treatment due to TEAEs (26%). The combination of pimasertib and voxtalisib showed poor long-term tolerability and limited anti-tumour activity in patients with advanced solid tumours.
         datePublished:2018-11-14T00:00:00Z
         dateModified:2018-11-14T00:00:00Z
         pageStart:1471
         pageEnd:1476
         sameAs:https://doi.org/10.1038/s41416-018-0322-4
         keywords:
            Drug development
            Targeted therapies
            Biomedicine
            general
            Cancer Research
            Epidemiology
            Molecular Medicine
            Oncology
            Drug Resistance
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41416-018-0322-4/MediaObjects/41416_2018_322_Fig1_HTML.png
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41416-018-0322-4/MediaObjects/41416_2018_322_Fig2_HTML.png
         isPartOf:
            name:British Journal of Cancer
            issn:
               1532-1827
               0007-0920
            volumeNumber:119
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Nature Publishing Group UK
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Alison M. Schram
               affiliation:
                     name:Memorial Sloan Kettering Cancer Center
                     address:
                        name:Memorial Sloan Kettering Cancer Center, New York, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
               name:Leena Gandhi
               affiliation:
                     name:New York University Perlmutter Cancer Center
                     address:
                        name:New York University Perlmutter Cancer Center, New York, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Monica M. Mita
               affiliation:
                     name:Cedars-Sinai Medical Center
                     address:
                        name:Cedars-Sinai Medical Center, Los Angeles, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Lars Damstrup
               affiliation:
                     name:Merck Serono
                     address:
                        name:Merck Serono, Darmstadt, Germany
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Frank Campana
               affiliation:
                     name:Sanofi-Aventis
                     address:
                        name:Sanofi-Aventis, Cambridge, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Manuel Hidalgo
               affiliation:
                     name:Beth Israel Deaconess Medical Center
                     address:
                        name:Beth Israel Deaconess Medical Center, Boston, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Enrique Grande
               affiliation:
                     name:Hospital Universitario Ramon y Cajal
                     address:
                        name:Hospital Universitario Ramon y Cajal, Madrid, Spain
                        type:PostalAddress
                     type:Organization
               type:Person
               name:David M. Hyman
               affiliation:
                     name:Memorial Sloan Kettering Cancer Center
                     address:
                        name:Memorial Sloan Kettering Cancer Center, New York, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Rebecca S. Heist
               affiliation:
                     name:Massachusetts General Hospital
                     address:
                        name:Massachusetts General Hospital, Boston, USA
                        type:PostalAddress
                     type:Organization
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:A phase Ib dose-escalation and expansion study of the oral MEK inhibitor pimasertib and PI3K/MTOR inhibitor voxtalisib in patients with advanced solid tumours
      description:This phase Ib study evaluated the safety, maximum-tolerated dose (MTD), pharmacokinetics, pharmacodynamics, and preliminary efficacy of pimasertib (MSC1936369B), a MEK1/2 inhibitor, in combination with voxtalisib (SAR245409), a pan-PI3K and mTORC1/mTORC2 inhibitor, in patients with advanced solid tumours. This study included a dose escalation and expansion in patients with select tumour types and alterations in the MAPK or PI3K pathways. A 3 + 3 design was used to determine MTD. Patients were evaluated for adverse events and tumour response. 146 patients were treated, including 63 in dose escalation and 83 in expansion. The MTD was pimasertib 90 mg and voxtalisib 70 mg daily. Based on the safety profile, the recommended phase 2 dose (RP2D) was pimasertib 60 mg and voxtalisib 70 mg. The most frequent treatment-emergent adverse events (TEAEs) were diarrhoea (75%), fatigue (57%), and nausea (50%). Responses included a complete response in one patient (1%), partial response in five (5%), and stable disease in 51 (46%). At the RP2D, 74 patients required dose interruption (73%), 20 required dose reduction (20%), and 26 discontinued treatment due to TEAEs (26%). The combination of pimasertib and voxtalisib showed poor long-term tolerability and limited anti-tumour activity in patients with advanced solid tumours.
      datePublished:2018-11-14T00:00:00Z
      dateModified:2018-11-14T00:00:00Z
      pageStart:1471
      pageEnd:1476
      sameAs:https://doi.org/10.1038/s41416-018-0322-4
      keywords:
         Drug development
         Targeted therapies
         Biomedicine
         general
         Cancer Research
         Epidemiology
         Molecular Medicine
         Oncology
         Drug Resistance
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41416-018-0322-4/MediaObjects/41416_2018_322_Fig1_HTML.png
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2Fs41416-018-0322-4/MediaObjects/41416_2018_322_Fig2_HTML.png
      isPartOf:
         name:British Journal of Cancer
         issn:
            1532-1827
            0007-0920
         volumeNumber:119
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Nature Publishing Group UK
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Alison M. Schram
            affiliation:
                  name:Memorial Sloan Kettering Cancer Center
                  address:
                     name:Memorial Sloan Kettering Cancer Center, New York, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
            name:Leena Gandhi
            affiliation:
                  name:New York University Perlmutter Cancer Center
                  address:
                     name:New York University Perlmutter Cancer Center, New York, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Monica M. Mita
            affiliation:
                  name:Cedars-Sinai Medical Center
                  address:
                     name:Cedars-Sinai Medical Center, Los Angeles, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Lars Damstrup
            affiliation:
                  name:Merck Serono
                  address:
                     name:Merck Serono, Darmstadt, Germany
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Frank Campana
            affiliation:
                  name:Sanofi-Aventis
                  address:
                     name:Sanofi-Aventis, Cambridge, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Manuel Hidalgo
            affiliation:
                  name:Beth Israel Deaconess Medical Center
                  address:
                     name:Beth Israel Deaconess Medical Center, Boston, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Enrique Grande
            affiliation:
                  name:Hospital Universitario Ramon y Cajal
                  address:
                     name:Hospital Universitario Ramon y Cajal, Madrid, Spain
                     type:PostalAddress
                  type:Organization
            type:Person
            name:David M. Hyman
            affiliation:
                  name:Memorial Sloan Kettering Cancer Center
                  address:
                     name:Memorial Sloan Kettering Cancer Center, New York, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Rebecca S. Heist
            affiliation:
                  name:Massachusetts General Hospital
                  address:
                     name:Massachusetts General Hospital, Boston, USA
                     type:PostalAddress
                  type:Organization
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:British Journal of Cancer
      issn:
         1532-1827
         0007-0920
      volumeNumber:119
Organization:
      name:Nature Publishing Group UK
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Memorial Sloan Kettering Cancer Center
      address:
         name:Memorial Sloan Kettering Cancer Center, New York, USA
         type:PostalAddress
      name:New York University Perlmutter Cancer Center
      address:
         name:New York University Perlmutter Cancer Center, New York, USA
         type:PostalAddress
      name:Cedars-Sinai Medical Center
      address:
         name:Cedars-Sinai Medical Center, Los Angeles, USA
         type:PostalAddress
      name:Merck Serono
      address:
         name:Merck Serono, Darmstadt, Germany
         type:PostalAddress
      name:Sanofi-Aventis
      address:
         name:Sanofi-Aventis, Cambridge, USA
         type:PostalAddress
      name:Beth Israel Deaconess Medical Center
      address:
         name:Beth Israel Deaconess Medical Center, Boston, USA
         type:PostalAddress
      name:Hospital Universitario Ramon y Cajal
      address:
         name:Hospital Universitario Ramon y Cajal, Madrid, Spain
         type:PostalAddress
      name:Memorial Sloan Kettering Cancer Center
      address:
         name:Memorial Sloan Kettering Cancer Center, New York, USA
         type:PostalAddress
      name:Massachusetts General Hospital
      address:
         name:Massachusetts General Hospital, Boston, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Alison M. Schram
      affiliation:
            name:Memorial Sloan Kettering Cancer Center
            address:
               name:Memorial Sloan Kettering Cancer Center, New York, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
      name:Leena Gandhi
      affiliation:
            name:New York University Perlmutter Cancer Center
            address:
               name:New York University Perlmutter Cancer Center, New York, USA
               type:PostalAddress
            type:Organization
      name:Monica M. Mita
      affiliation:
            name:Cedars-Sinai Medical Center
            address:
               name:Cedars-Sinai Medical Center, Los Angeles, USA
               type:PostalAddress
            type:Organization
      name:Lars Damstrup
      affiliation:
            name:Merck Serono
            address:
               name:Merck Serono, Darmstadt, Germany
               type:PostalAddress
            type:Organization
      name:Frank Campana
      affiliation:
            name:Sanofi-Aventis
            address:
               name:Sanofi-Aventis, Cambridge, USA
               type:PostalAddress
            type:Organization
      name:Manuel Hidalgo
      affiliation:
            name:Beth Israel Deaconess Medical Center
            address:
               name:Beth Israel Deaconess Medical Center, Boston, USA
               type:PostalAddress
            type:Organization
      name:Enrique Grande
      affiliation:
            name:Hospital Universitario Ramon y Cajal
            address:
               name:Hospital Universitario Ramon y Cajal, Madrid, Spain
               type:PostalAddress
            type:Organization
      name:David M. Hyman
      affiliation:
            name:Memorial Sloan Kettering Cancer Center
            address:
               name:Memorial Sloan Kettering Cancer Center, New York, USA
               type:PostalAddress
            type:Organization
      name:Rebecca S. Heist
      affiliation:
            name:Massachusetts General Hospital
            address:
               name:Massachusetts General Hospital, Boston, USA
               type:PostalAddress
            type:Organization
PostalAddress:
      name:Memorial Sloan Kettering Cancer Center, New York, USA
      name:New York University Perlmutter Cancer Center, New York, USA
      name:Cedars-Sinai Medical Center, Los Angeles, USA
      name:Merck Serono, Darmstadt, Germany
      name:Sanofi-Aventis, Cambridge, USA
      name:Beth Israel Deaconess Medical Center, Boston, USA
      name:Hospital Universitario Ramon y Cajal, Madrid, Spain
      name:Memorial Sloan Kettering Cancer Center, New York, USA
      name:Massachusetts General Hospital, Boston, USA

Social Networks {👍}(1)

• https://twitter.com/BrJCancer

External Links {🔗}(67)

• What is the earnings of https://doi.org/10.1016%2Fj.cell.2007.06.009?
• Monthly income for http://scholar.google.com/scholar_lookup?&title=AKT%2FPKB%20signaling%3A%20navigating%20downstream&journal=Cell&doi=10.1016%2Fj.cell.2007.06.009&volume=129&pages=1261-1274&publication_year=2007&author=Manning%2CBD&author=Cantley%2CLC
• Get to know https://doi.org/10.1038%2Fnrc1503's earnings
• What's the financial outcome of http://scholar.google.com/scholar_lookup?&title=Targeting%20the%20mitogen-activated%20protein%20kinase%20cascade%20to%20treat%20cancer&journal=Nat.%20Rev.%20Cancer&doi=10.1038%2Fnrc1503&volume=4&pages=937-947&publication_year=2004&author=Sebolt-Leopold%2CJS&author=Herrera%2CR?
• How much profit does https://doi.org/10.1038%2Fnature00766 generate?
• How much profit is http://scholar.google.com/scholar_lookup?&title=Mutations%20of%20the%20BRAF%20gene%20in%20human%20cancer&journal=Nature&doi=10.1038%2Fnature00766&volume=417&pages=949-954&publication_year=2002&author=Davies%2CH making per month?
• https://doi.org/10.1002%2Fpath.2796 income
• How much does http://scholar.google.com/scholar_lookup?&title=KRAS%20and%20BRAF%3A%20drug%20targets%20and%20predictive%20biomarkers&journal=J.%20Pathol.&doi=10.1002%2Fpath.2796&volume=223&pages=219-229&publication_year=2011&author=Vakiani%2CE&author=Solit%2CDB earn?
• Earnings of https://doi.org/10.1038%2Fnrd4389
• How much profit does http://scholar.google.com/scholar_lookup?&title=Drugging%20the%20undruggable%20RAS%3A%20Mission%20possible%3F&journal=Nat.%20Rev.%20Drug.%20Discov.&doi=10.1038%2Fnrd4389&volume=13&pages=828-851&publication_year=2014&author=Cox%2CAD&author=Fesik%2CSW&author=Kimmelman%2CAC&author=Luo%2CJ&author=Der%2CCJ generate?
• Monthly income for https://doi.org/10.1016%2Fj.cell.2015.05.044
• What's the monthly money flow for http://scholar.google.com/scholar_lookup?&title=Genomic%20classification%20of%20cutaneous%20melanoma&journal=Cell&doi=10.1016%2Fj.cell.2015.05.044&volume=161&pages=1681-1696&publication_year=2015?
• Monthly income for https://doi.org/10.1038%2Fonc.2008.247
• How much profit is http://scholar.google.com/scholar_lookup?&title=The%20PTEN-PI3K%20pathway%3A%20of%20feedbacks%20and%20cross-talks&journal=Oncogene&doi=10.1038%2Fonc.2008.247&volume=27&pages=5527-5541&publication_year=2008&author=Carracedo%2CA&author=Pandolfi%2CPP making per month?
• How much does https://doi.org/10.1002%2Fijc.28236 rake in every month?
• What's the total monthly financial gain of http://scholar.google.com/scholar_lookup?&title=Antitumor%20activity%20of%20pimasertib%2C%20a%20selective%20MEK%201%2F2%20inhibitor%2C%20in%20combination%20with%20PI3K%2FmTOR%20inhibitors%20or%20with%20multi-targeted%20kinase%20inhibitors%20in%20pimasertib-resistant%20human%20lung%20and%20colorectal%20cancer%20cells&journal=Int.%20J.%20Cancer&doi=10.1002%2Fijc.28236&volume=133&pages=2089-2101&publication_year=2013&author=Martinelli%2CE?
• What's the monthly income of https://doi.org/10.1200%2Fjco.2011.29.15_suppl.3019?
• What are the total earnings of http://scholar.google.com/scholar_lookup?&title=Safety%20and%20evidence%20of%20activity%20of%20MSC1936369%2C%20an%20oral%20MEK1%2F2%20inhibitor%2C%20in%20patients%20with%20advanced%20malignancies&journal=J.%20Clin.%20Oncol.&doi=10.1200%2Fjco.2011.29.15_suppl.3019&volume=29&pages=3019-3019&publication_year=2011&author=Houede%2CN?
• See how much https://doi.org/10.18632%2Foncotarget.188 makes per month
• How much does http://scholar.google.com/scholar_lookup?&title=Targeting%20the%20PI3K%2FAkt%2FmTOR%20pathway--beyond%20rapalogs&journal=Oncotarget&doi=10.18632%2Foncotarget.188&volume=1&pages=530-543&publication_year=2010&author=Markman%2CB&author=Dienstmann%2CR&author=Tabernero%2CJ bring in each month?
• What's the total monthly financial gain of https://doi.org/10.1093%2Fannonc%2Fmdp347?
• Revenue of http://scholar.google.com/scholar_lookup?&title=Status%20of%20PI3K%20inhibition%20and%20biomarker%20development%20in%20cancer%20therapeutics&journal=Ann%20Oncol.%20Off.%20J.%20Eur.%20Soc.%20Med.%20Oncol.&doi=10.1093%2Fannonc%2Fmdp347&volume=21&pages=683-691&publication_year=2010&author=Markman%2CB&author=Atzori%2CF&author=P%C3%A9rez-Garc%C3%ADa%2CJ&author=Tabernero%2CJ&author=Baselga%2CJ
• Get to know https://doi.org/10.1158%2F1535-7163.MCT-13-0709's earnings
• What's the income of http://scholar.google.com/scholar_lookup?&title=Characterization%20of%20the%20activity%20of%20the%20PI3K%2FmTOR%20inhibitor%20XL765%20%28SAR245409%29%20in%20tumor%20models%20with%20diverse%20genetic%20alterations%20affecting%20the%20PI3K%20pathway&journal=Mol.%20Cancer%20Ther.&doi=10.1158%2F1535-7163.MCT-13-0709&volume=13&pages=1078-1091&publication_year=2014&author=Yu%2CP?
• Monthly income for https://doi.org/10.1158%2F1078-0432.CCR-13-2403
• http://scholar.google.com/scholar_lookup?&title=Phase%20I%20safety%2C%20pharmacokinetic%2C%20and%20pharmacodynamic%20study%20of%20SAR245409%20%28XL765%29%2C%20a%20novel%2C%20orally%20administered%20PI3K%2FmTOR%20inhibitor%20in%20patients%20with%20advanced%20solid%20tumors&journal=Clin.%20Cancer%20Res.%20J.%20Am.%20Assoc.%20Cancer%20Res.&doi=10.1158%2F1078-0432.CCR-13-2403&volume=20&pages=2445-2456&publication_year=2014&author=Papadopoulos%2CKP income
• How much does http://scholar.google.com/scholar_lookup?&title=New%20response%20evaluation%20criteria%20in%20solid%20tumours%3A%20revised%20RECIST%20guideline%20%28version%201.1%29&journal=Eur.%20J.%20Cancer%20Oxf.%20Engl.%201990.&volume=45&pages=228-247&publication_year=2009&author=Eisenhauer%2CEA make?
• How much money does https://doi.org/10.1158%2F1078-0432.CCR-14-1814 generate?
• Get to know what's the income of http://scholar.google.com/scholar_lookup?&title=A%20phase%20Ib%20dose-escalation%20study%20of%20the%20oral%20pan-PI3K%20inhibitor%20buparlisib%20%28BKM120%29%20in%20combination%20with%20the%20oral%20MEK1%2F2%20inhibitor%20trametinib%20%28GSK1120212%29%20in%20patients%20with%20selected%20advanced%20solid%20tumors&journal=Clin.%20Cancer%20Res.%20J.%20Am.%20Assoc.%20Cancer%20Res.&doi=10.1158%2F1078-0432.CCR-14-1814&volume=21&pages=730-738&publication_year=2015&author=Bedard%2CPL
• Get to know https://link.springer.com/doi/10.1007/s11523-017-0530-5's earnings
• How much does http://scholar.google.com/scholar_lookup?&title=A%20Multi-Arm%20Phase%20I%20Study%20of%20the%20PI3K%2FmTOR%20Inhibitors%20PF-04691502%20and%20Gedatolisib%20%28PF-05212384%29%20plus%20Irinotecan%20or%20the%20MEK%20Inhibitor%20PD-0325901%20in%20Advanced%20Cancer&journal=Target%20Oncol.&doi=10.1007%2Fs11523-017-0530-5&volume=12&pages=775-785&publication_year=2017&author=Wainberg%2CZA bring in each month?
• What's the financial gain of https://link.springer.com/doi/10.1007/s10637-017-0442-3?
• Discover the revenue of http://scholar.google.com/scholar_lookup?&title=Phase%20I%20trial%20of%20MEK%201%2F2%20inhibitor%20pimasertib%20combined%20with%20mTOR%20inhibitor%20temsirolimus%20in%20patients%20with%20advanced%20solid%20tumors&journal=Invest.%20New%20Drugs&doi=10.1007%2Fs10637-017-0442-3&volume=35&pages=616-626&publication_year=2017&author=Mita%2CM
• Explore the financials of https://link.springer.com/doi/10.1007/s10637-016-0377-0
• How much profit does http://scholar.google.com/scholar_lookup?&title=A%20phase%20Ib%20dose-escalation%20study%20of%20the%20MEK%20inhibitor%20trametinib%20in%20combination%20with%20the%20PI3K%2FmTOR%20inhibitor%20GSK2126458%20in%20patients%20with%20advanced%20solid%20tumors&journal=Invest.%20New%20Drugs&doi=10.1007%2Fs10637-016-0377-0&volume=34&pages=740-749&publication_year=2016&author=Grilley-Olson%2CJE generate?
• What's the financial outcome of https://citation-needed.springer.com/v2/references/10.1038/s41416-018-0322-4?format=refman&flavour=references?
• Learn about the earnings of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Alison%20M.%20Schram
• What's the financial intake of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Alison%20M.%20Schram%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
• How much does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Leena%20Gandhi net monthly?
• How much income does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Leena%20Gandhi%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en have?
• How much cash flow does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Monica%20M.%20Mita have monthly?
• How much income is https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Monica%20M.%20Mita%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en earning monthly?
• What's the monthly income of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Lars%20Damstrup?
• https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Lars%20Damstrup%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en income
• What's the monthly income of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Frank%20Campana?
• How much does https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Frank%20Campana%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en make?
• What's the revenue for https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Manuel%20Hidalgo?
• https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Manuel%20Hidalgo%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en's total income per month
• Earnings of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Enrique%20Grande
• What is the monthly revenue of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Enrique%20Grande%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
• What's the financial gain of https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=David%20M.%20Hyman?
• What's the financial intake of https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22David%20M.%20Hyman%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en?
• How much does https://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=search&term=Rebecca%20S.%20Heist make?
• Check the income stats for https://scholar.google.co.uk/scholar?as_q=&num=10&btnG=Search+Scholar&as_epq=&as_oq=&as_eq=&as_occt=any&as_sauthors=%22Rebecca%20S.%20Heist%22&as_publication=&as_ylo=&as_yhi=&as_allsubj=all&hl=en
• What's the financial gain of https://static-content.springer.com/esm/art%3A10.1038%2Fs41416-018-0322-4/MediaObjects/41416_2018_322_MOESM1_ESM.docx?
• Learn about the earnings of https://s100.copyright.com/AppDispatchServlet?title=A%20phase%20Ib%20dose-escalation%20and%20expansion%20study%20of%20the%20oral%20MEK%20inhibitor%20pimasertib%20and%20PI3K%2FMTOR%20inhibitor%20voxtalisib%20in%20patients%20with%20advanced%20solid%20tumours&author=Alison%20M.%20Schram%20et%20al&contentID=10.1038%2Fs41416-018-0322-4©right=Cancer%20Research%20UK&publication=0007-0920&publicationDate=2018-11-14&publisherName=SpringerNature&orderBeanReset=true&oa=CC%20BY
• Financial intake of https://crossmark.crossref.org/dialog/?doi=10.1038/s41416-018-0322-4
• How much income does https://citation-needed.springer.com/v2/references/10.1038/s41416-018-0322-4?format=refman&flavour=citation have?
• How much money does https://doi.org/10.1186/s12943-025-02289-8 make?
• Monthly income for https://doi.org/10.1038/s41416-025-03035-z
• How much does https://doi.org/10.1186/s12943-024-02072-1 generate monthly?
• What's the income generated by https://doi.org/10.1038/s41467-024-50063-z each month?
• How much does https://doi.org/10.1038/s41467-024-46811-w generate monthly?
• Learn about the earnings of https://www.protocols.io/
• https://www.natureindex.com/'s revenue stream
• What's the income of http://www.naturechina.com?
• How much does https://www.natureasia.com/ja-jp pull in?

Analytics and Tracking {📊}

• Google Tag Manager

Libraries {📚}

• Prism.js
• Zoom.js

Emails and Hosting {✉️}

Mail Servers:

• mxa-002c5801.gslb.pphosted.com
• mxb-002c5801.gslb.pphosted.com

Name Servers:

• pdns1.ultradns.net
• pdns2.ultradns.net
• pdns3.ultradns.org
• pdns4.ultradns.org
• pdns5.ultradns.info
• pdns6.ultradns.co.uk

CDN Services {📦}

• Crossref